Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG2512
- Development stage
- Phase 1
- Lead developer
- Maijin Biomedical Technology
- Administration
- Intravenous
01
Overview
MG2512 is an investigational therapeutic being developed by Shanghai Mabgen Biopharmaceutical Technology for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, where it is being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies who have progressed on or are unsuitable for standard therapies. The drug is administered as an injection. While specific details regarding its molecular target have not been widely publicized in clinical trial registries, it belongs to the portfolio of a company specializing in recombinant protein and monoclonal antibody technologies.
Beyond the preview
Go deeper on MG2512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG2512.